Sen. Bernie Sanders (I-VT) is set to question Novo Nordisk CEO Lars Jorgensen on Tuesday over the drugmaker's prices for its popular weight-loss and diabetes medicines that can cost Americans more than $1,000 a month. Sanders is expected to challenge the CEO during a hearing of the Senate HELP Committee, which he chairs, on why the company charges American payors more for the lifesaving drugs than any other country. Ozempic and Wegovy carry U.S list prices of $935.77 and $1,349.02 respectively for a month's supply, which Sanders has previously argued is far higher than the respective $59 and $92 price tags they carry in some European countries. Jorgensen says 99% of U.S. commercial insurance plans now cover Ozempic and around half cover Wegovy. More than 80% of U.S. patients with insurance coverage for the drugs pay less than $25 for a month's supply and 90% pay less than $50.
